Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05451849 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | PHASE1 | ACTIVE NOT_RECRUITING | 6 | — | — | Jun 21, 2022 | Oct 30, 2028 | Aug 27, 2025 | 7 | United States |
Phase 1 -The number and percent of patients in the DLT evaluable set who experienced DLTs from the first administration of study drug up to 28 days post study drug treatment will be summarized by dosing group
ORR is defined as incidence of complete responses or partial responses as assessed by RECIST v1.1
DCR defined as a composite of ORR and stable disease (SD) lasting at least 8 weeks.
| Arm | Type | Description |
|---|---|---|
| Lymphodepletion followed by TC-510 | EXPERIMENTAL | Lymphodepletion (fludarabine and cyclophosphamide) followed by TC-510 T cells |
| Name | Type | Description |
|---|---|---|
| TC-510 | BIOLOGICAL | TC-510 |
| Fludarabine | DRUG | Fludarabine |
| Cyclophosphamide | DRUG | Cyclophosphamide |
Inclusion Criteria: * Patient is \> 18 years of age at the time the Informed Consent is signed. * Patient has a pathologically confirmed diagnosis of either MPM, Serous Ovarian Adenocarcinoma, Pancreatic Adenocarcinoma, TNBC, and Colorectal Cancer * Patient's tumor has been reviewed with confirmed ...